


# Galenica Group Octavian Seminar 2021

Felix Burkhard, CFO 15 January 2021



# Covid-19 Exceptional year 2020






## Covid-19


#### **GALENICA**

# Exceptional year 2020



## Swiss pharmaceutical market monthly development

Value (ex-factory) YTD November 2020: CHF 5'750.1 million CHF +160.1 million / +2.9%



Source: APO/SD/DRO/SPI Index, Swissmedic A, B, C, D
Medicines Swissmedic lists A, B, C, D, sold from suppliers and wholesalers to hospitals, physicians and drugstores




- → Galenica Group net sales +2% to +5%
- → EBIT (excluding the effects of IAS19 & IFRS16) approximately on prior year level
- → Dividend for 2020 at least at prior year level



## **Pharmacies Expansion**







## Online Pharmacy Expansion



**Jetzt Ihre Medikamente bequem liefern lassen.** Entdecken Sie Ihre Online-Apotheke Amavita.



Jetzt Ihre Medikamente bequem liefern lassen.



Entdecken Sie Ihre Online-Apotheke Coop Vitality.

Für mehr Komfort.







## **Product Portfolio Expansion**























#### **GALENICA**

## Product Portfolio Expansion Acquisition of the Hedoga Group on 1 July 2020



















## Further progress with IT and logistics projects

**GALENICA** 

New ERP system at Alloga and Galexis

Modernisation of Galexis distribution centre in Lausanne-Ecublens








# Regulatory and political environment




## Authorities: measures and projects




<sup>1)</sup> Swissmedic categories C, D

## Proposal of new SBR V contract and distribution margin model



## Authorities: measures and projects



<sup>1)</sup> Swissmedic categories C, D



## Leadership handover on 1st April 2020

Marc Werner, CEO Galenica Group as of 1st April 2020




Jean-Claude Clémençon, retired after more than 20 years of commitment at Galenica

## **Strategic Programmes**



→ Implement strategy with focus and speed



## Focus of the Strategic Programmes

#### **Omni-Channel:**

Offer customers the best experience on all channels, anytime, anywhere.

## Care:

Strengthen the role of pharmacies with healthcare offers and partnerships.

## **Professionals**:

Strong partner for all stakeholders in the healthcare sector.

## **Efficiency**:

Secure earnings, release funds for investments.


## **Transformation:**

Implement strategy powerfully, effectively, quickly and successfully.



18

## Management structure Galenica Group as of 1st January 2021



- \* Executive Committee
- \*\* extended Executive Comittee
- 1) Joint venture with Coop

#### **Priorities 2021**

## **Omni-Channel**

- Expansion of product portfolio and pharmacy network
- Optimisation of online offering and integration in offline world

#### Care

Development of healthcare services and partnerships

## **Professionals**

Expansion and optimisation of services for business partners

## **Efficiency**

- Advance construction work in Lausanne-Ecublens
- and implementation of new ERP System

#### **Transformation**

Bring the new organisation to life



## **Questions & Answers**



#### Disclaimer

#### **Disclaimer Galenica**

Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.

#### **Disclaimer IQVIA**

© 2020, IQVIA Solutions GmbH

All rights reserved. The information may not be duplicated, stored, processed further, nor be made accessible in whole or in part to any third party without prior express and valid written permission of IQVIA Solutions GmbH. Terms used in connection with data/figures such as "patient", "doctor", "medical practice", "prescriber", or "pharmacy" do not designate any personal data but exclusively anonymous information (according to applicable, valid data protection laws).

IQVIA utilizes highly sophisticated technologies and methods in order to ensure that all its Information Services meet the applicable data protection requirements, regardless of the way data are combined.